Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first-to-market Olumiant. The European Commission has ...

Pfizer’s Litfulo is the first treatment approved for treating adolescents with severe alopecia areata. The drug’s approval also covers adults, were it will compete against Eli Lilly’s Olumiant.

"Obviously it's my favorite thing, and it's changed my life in so many ways," continues Tisdale, who has partnered with Pfizer and Litfulo, an FDA-approved pill for people 12 and older with severe ...

Called Ritlecitinib or Litfulo, it could help thousands of people ... including a reduced price from the manufacturer Pfizer. Helen Knight, director of medicines evaluation at NICE, said: "Our ...

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products ...